Revizinone

Drug Profile

Revizinone

Alternative Names: R 80122

Latest Information Update: 16 Nov 1999

Price : $50

At a glance

  • Originator Ortho-McNeil
  • Developer Janssen L.P.; Ortho-McNeil
  • Class Cardiotonics
  • Mechanism of Action Type 3 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Heart failure; Ischaemic heart disorders

Most Recent Events

  • 16 Nov 1999 No-Development-Reported for Ischaemic heart disorders in Germany (IV)
  • 16 Nov 1999 No-Development-Reported for Heart failure in USA (Unknown route)
  • 16 Nov 1999 No-Development-Reported for Heart failure in Belgium (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top